medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Increasing burden of opioid overdose mortality in the United States: Years of life lost by age, race, and state from 2019-2021

Anne H. Hébert and Alison L. Hill
Institute for Computational Medicine, Johns Hopkins University

Corresponding author email:
alhill@jhmi.edu

Affiliations:
Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD

ORCIDs:
Alison L. Hill 0000-0002-6583-3623
Anne H. Hébert 000-0002-6767-1249

Abstract

The United States' opioid crisis is worsening, but the nationwide burden has not been characterized during the COVID-19 pandemic. In this study we calculate years of life lost to opioid overdose deaths by demographic group and examine trends from 2019 to 2021.

Using the Multiple Cause of Death dataset from CDC WONDER, we extracted opioid overdose deaths stratified by race/ethnicity, age, and state, and estimated crude and age-adjusted mortality rates, years of life lost, and reduction in life expectancy at birth.

Increasing annually, opioid overdose deaths reached 80,411 in 2021, leading to 3 million years of life lost, and reducing life expectancy by 0.65 years. From 2019 to 2021, opioid overdose death rates increased across all groups. American Indian/Alaska Native and Black/African American men now experience the highest burden, with 1,500 years of life lost per 100,000, life expectancies at birth reduced by almost 1 year, and 46 and 51 deaths per 100,000, respectively.

This study highlights the continued growth of the opioid crisis, and the surge in years of life lost coinciding with COVID-19. There is an urgent need for more effective interventions, particularly in light of this epidemic's changing demographics.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Main text

The opioid epidemic is an urgent public health issue in the United States. With use and misuse increasing since the mid-1990s, the US is now the largest consumer of opioids globally [1]. Fatal opioid overdoses in the US have increased more than tenfold since 1999, reaching a record of 80,411 deaths in 2021 [2]. The initial rise in opioid-related deaths is commonly attributed to rising prescription rates following aggressive marketing by the pharmaceutical industry, which was inadequately regulated by the Food and Drug Administration (FDA) [3–7]. In attempts to curb the epidemic, some state and national regulations on opioid prescriptions were implemented [8,9], and in 2016 the Centers for Disease Control and Prevention (CDC) issued prescription recommendations [10]. While this reduced prescriptions nationally [11–14], opioid overdose deaths continue to rise. The crisis is now driven primarily by illicitly manufactured opioids [15,16]. Following the onset of the COVID-19 pandemic, there was a surge in both fatal and non-fatal opioid overdoses in 2020 [17–19].

Opioids are a class of drugs that block pain signals by binding to opioid receptors on neurons throughout the nervous system. Recreationally used opioids can be derived from poppies (e.g., morphine, opium), created semi-synthetically by chemical modification of naturally-occurring compounds (e.g., heroin, oxycodone) or created completely synthetically (e.g., fentanyl, tramadol). Opioids are prescribed to treat moderate to severe pain, either as a short-term or chronic treatment. However, prescription opioids are also used recreationally for euphoric effects, by individuals obtaining them either through prescriptions or other means [20–26]. An estimated 12.5% of US adults with an opioid prescription (11.5 million) misused it in 2015, and 2% of prescribed opioid users (or up to 12% for long-term chronic pain prescriptions) develop opioid use disorder (OUD) [27,28]. OUD includes addiction, increased tolerance, and withdrawal symptoms when use is stopped, and contributes to health and social problems, such as income-generating criminal activity [29–31]. Individuals with OUD have 10 times higher mortality than the general population, and experience overdose death rates of about 8 per 1,000 person-years [32,33]. While effective medications exist for OUD, it is estimated that only 28% of people needing treatment receive it (and only 43% receive any intervention) [34,35].

While opioid overdose mortality rates are alarmingly high, measures of deaths alone do not account for the young age at which most opioid-related deaths occur, compared to other causes of death [36]. Years of life lost is a particularly fitting metric, estimating how many additional years individuals would have lived, had they not died prematurely from the cause in question [37]. The YLL due to the opioid crisis have been estimated for Ontario, Canada between 1990 and 2010 [38] , in the US between 2001 and 2016 [39], and for the state of Ohio in 2016 [40]. The YLL to opioids in Washington State were compared across racial and ethnic groups, by educational attainment, and urbanicity [41]. There are estimates of the YLL from fatal overdoses involving opioids and other drugs in adolescents [42] and in Black women [43]. Studies have examined the impact of opioid-related deaths on the US life expectancy at birth in 2015 [44], by state and opioid type in 2016 [45], and across demographic groups in 2017 [46]. However, these metrics of burden have not been used to evaluate recent impacts of the crisis, or to compare comprehensively across demographic groups.

In this study, we quantify the evolution of the opioid crisis in the years 2019, 2020 and 2021, coinciding with the onset of the COVID-19 pandemic. For each year in question, we estimate the years of life lost to opioid overdose deaths in the United States, in addition to estimating how much this reduces the US population's life expectancy at birth. We compare these metrics of burden across demographic groups, highlighting which groups have seen the largest increases

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

in the last few years. We also examine how the number of deaths, death rates, and age patterns vary over time and by demographic group.

Methods

Data

This study uses data from the Multiple Cause of Death database from CDC WONDER, the Wide-ranging ONline Database for Epidemiological Research. For each year in question (2019, 2020 and 2021), we accessed data on the number of deaths, and crude and age-adjusted death rates by cause of death, with the option of stratifying by age, gender, race, Hispanic origin, or state. At the time of writing, 2021 is the most recent year for which data is available on CDC WONDER. All age-adjusted rates reported here used the 2000 Standard Population. In this database, when fewer than 10 death counts are in any given category, the statistics are suppressed to ensure confidentiality. For this reason, we avoid subdividing by more variables than necessary, and when stratifying opioid overdose deaths by age, we use 5-year age groups. The mortality data are based on death certificates of US residents in all counties. Causes of death are categorized by Underlying Cause of Death and by Multiple Cause of Death, using ICD-10 codes (International Classification of Diseases). For opioid overdose deaths, we filter for deaths with both an underlying cause of death code indicating drug poisoning (X40-44: unintentional, X60-64: suicide, X85: homicide, Y10-14: undetermined intent) and a multiple cause of death indicating an opioid (T40.0-T40.4: Opium, Heroin, Natural and Semisynthetic Opioids, Methadone, and Synthetic Opioids, and T40.6: Other and Unspecified Narcotics). This is a standard method of classifying opioid-related overdose deaths [3].

CDC WONDER reports gender in 2 categories: “male” or “female”. We used the option to subdivide into 6 race categories: American Indian/Alaska Native (AI/AN), Asian, Black or African American, Native Hawaiian or Other Pacific Islander (NHOPI), white, and “More than one race”. Ethnic origin is reported separately, with 3 categories: Hispanic or Latino, non-Hispanic or Latino, or “Not Stated”. We omit individuals with missing ethnic origin (“Not Stated”), who account for only 0.2% of all deaths and 0.6% of opioid overdose deaths in 2021. This leads to 12 remaining combinations of race and Hispanic origin, many of which with very few individuals (such as Hispanic origin and NHOPI race). For this reason, we combine race and ethnic origin, forming 7 groups: one containing all individuals of Hispanic or Latino origin and of any race (of whom 96% identified as “white”), and 6 groups containing individuals of non-Hispanic or Latino origin, grouped by race.

This study also uses 2019 and 2020 US population period life tables from the NVSS, reported by gender and race/ethnicity, using groups similar to those described above [47,48]. Life tables track the mortality experience of a population, and are commonly used in demography and actuarial science [49–51].

Life expectancy and years of life lost

We estimate the impact of the opioid crisis on life expectancy in the US. Life expectancy is the average remaining length of life of individuals at each age, assuming that current age-specific mortality patterns were to remain constant throughout their lifetimes. The reduction in life expectancy due to a cause of death accounts for both the number of deaths, and the age at

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

which individuals are dying. In general, the impact of a particular cause of death on life expectancy can be estimated by first finding what the life expectancy would have been in the absence of the cause (the counterfactual life expectancy). The counterfactual age-dependent mortality rates in the absence of the cause of death in question are estimated by subtracting the number of deaths due to this cause from the total deaths, for each age. From these counterfactual mortality rates, the life expectancy in the absence of the cause can be calculated using standard life table equations [47]. For each age, the difference between real life expectancies (rLE_{age}) and the estimated counterfactual life expectancies (cLE_{age}) reveals the impact that the cause in question has on life expectancy:

$$\Delta LE_{age} = cLE_{age} - rLE_{age}$$

Using this method, we estimate the reduction in life expectancy at birth due to the opioid epidemic, for the entire US population, and by demographic group.

We can calculate years of life lost (YLL) due to the particular cause of death, by multiplying the number of deaths at each age due to this particular cause (N_{age}) by the counterfactual life expectancy at that age in the absence of the cause of death (cLE_{age}). Total YLL are obtained by summing over all ages:

$$YLL = \sum_{age} (N_{age} \times cLE_{age})$$

Here, we estimated YLL in the US due to the opioid crisis in the years 2019, 2020 and 2021, separately for each demographic group (race and gender). Due to the CDC WONDER's suppression of counts <10 (see above) we accessed opioid overdose death counts in 5-year age groups, and assumed that the deaths occurred at the midpoint of the age intervals.

Previous studies of the YLL from overdose deaths have estimated the years lost from one individual's death by comparing their age at death to either a specific cutoff age [41], or to the remaining LE for that age [38–40,42,43]. In this study, we compare the age at death to the estimated counterfactual remaining LE. For major causes of death that have a significant impact on the population's life expectancy, accounting for the resulting reduction in LE avoids underestimating the YLL.

CDC WONDER censors population counts above the age of 85, meaning we have no denominator for calculating death rates for those ages. However, since only 0.1% of opioid overdose deaths occurred at ages 85-100 in 2019-2021, we assume that these deaths do not impact the population's life expectancy. We therefore complete our counterfactual life tables with data from the NVSS life tables, scaled by a multiplicative factor in order to match the values at age 84. For 2019 and 2020 estimates we used the corresponding NVSS values, and for 2021 we used the 2020 NVSS values since 2021 tables were not released at the time of writing.

These results and more can be found online on our interactive web app, which visualizes data on the opioid crisis: https://annehebert.github.io/dashboard.html

Results

Opioid overdose deaths in the United States have been on the rise since the mid-1990s (Figure 1A). In particular, there was a 38% increase in opioid-related deaths from 2019 to 2020, and a

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

17% increase from 2020 to 2021, reaching 80,411 deaths in 2021 (Table 1). More men die of opioid-related deaths each year than women: in 2021, 70% of deaths (56,757/80,411) were among men (Table 1). In all demographic groups, opioid overdose deaths have substantially increased over time. Of the individuals dying of opioid overdoses in 2021, 53,022 were white, 14,537 Black, 9,921 Hispanic, 932 American Indian/Alaska Native (AI/AN), 533 Asian and 62 Native Hawaiian and Other Pacific Islander (NHOPI), as well as 926 non-Hispanic individuals of more than one race (Table 1). Although opioid overdose deaths are distributed across all age groups, most deaths are in 25-44 year olds.

Both prescription drugs and a variety of illicitly manufactured opioids are responsible for fatal opioid overdoses. The sharp increase in overdose deaths since 2015, and in particular since 2019, is primarily driven by synthetic opioids (Table 1). In 2021, 70,601 overdose deaths involved synthetic opioids (mainly fentanyl [52]), nearly doubled since 2019 (Table 1). The synthetic opioid overdose death rate increased from 3 deaths per 100,000 people in 2015 to 11 in 2019, and then 21 per 100,000 in 2021 (Figure 1B). The rate of overdose deaths involving heroin rose from 2010 to 2015 (from 1 to 4 per 100,000 people), but has since seen a decrease to 2.8 deaths per 100,000 in 2021.



Figure 1: Trends in opioid overdose deaths in the United States from 1999 to 2021. A) Total number of overdose deaths each year involving an opioid. B) Annual rates (per 100,000 population) of overdose deaths, by type of opioid involved. Note that some deaths involve more than one type of opioid. Synthetic Opioids include, for example, drugs such fentanyl (and its derivatives) and tramadol, but excludes methadone. Natural and Semisynthetic Opioids include, for example, oxycodone, hydrocodone, and morphine. Heroin is categorized separately although it is also a semisynthetic opioid. Methadone, a synthetic opioid prescribed to treat opioid use disorder, is categorized separately. Other and Unspecified Narcotics include deaths due to opioid or cocaine-like substances, or mixtures thereof, that were not further sub-categorized on the death certificate.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

		2021	2020	2019	2010	2000
Total opioid overdose deaths		80,411	68,630	49,860	21,089	8,407
By gender	Male	56,757	48,660	34,635	13,355	6,143
	Female	23,654	19,970	15,225	7,734	2,264
By race/ethnicity	White	53,022	46,961	35,779	17,936	6,207
	Black or African American	14,537	11,338	7,331	1,339	1,142
	Hispanic origin (all races)	9,921	7,966	5,264	1,373	868
	American Indian or Alaska Native	932	669	421	236	63
	Asian	533	527	314	118	34
By age	< 15	219	143	89	77	31
	15-24	6,312	5,986	3,725	2,387	728
	25-34	20,279	18,239	13,309	4,675	1,640
	35-44	21,200	17,666	12,425	4,761	3,277
	45-54	15,599	13,258	10,015	5,941	2,183
	55-64	13,080	10,445	7,978	2,700	395
	65-74	3,420	2,554	1,977	374	89
	75-84	312	254	265	103	36
	85+	82	76	72	70	18
By opioid type	Synthetic opioids	70,601	56,516	36,359	3,007	782
	Natural and semisynthetic opioids	13,618	13,471	11,886	10,943	2,917
	Heroin	9,173	13,165	14,019	3,036	1,842
	Methadone	3,678	3,543	2,740	4,577	986
	Other and unspecified narcotics	1,452	1,654	1,549	2,386	2,875

Table 1: Deaths involving opioids in 2021, 2020, 2019, 2010 and 2000 in the United States. The number of opioid overdose deaths each year, stratified by gender, race and ethnic origin, age, or opioid type involved. All individuals of Hispanic origin are aggregated, regardless of race (see Methods). Race categories reported by CDC changed in 2018, but we only include here the race and ethnic origin groups with a number of deaths high enough that we were able to estimate the years of life lost. Note that in many cases more than one type of opioid is involved.

A majority of opioid overdose deaths occur among younger people. In the earlier stages of this crisis, more middle-aged adults were dying than younger adults (Figure 2A). For example, in 2010 a majority of deaths among women occurred around 50 years old, and deaths among men were fairly evenly distributed across ages (Figure 2A). However, in recent years there has been a significant increase in deaths among young adults, bringing the median age of individuals dying of opioid overdoses to 40 years old for men, and 41 for women in 2021. Despite the large difference in the raw number of opioid-related deaths between genders in younger age groups, the percentage of total deaths at each age that involve opioids is more similar between genders (Figure 2B). Nationwide, in 2021, more than 20% of all deaths of women at each age between 20-34 years involved opioids, with the highest contribution being 24% of 26-29 year old deaths. More than 20% of all deaths of men at each age between 23-39 years old involved opioids, with the highest being 27% of 31 year old deaths (Figure 2B).

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .



Figure 2: Age distributions of opioid overdose deaths in the United States. Age distribution of opioid overdose deaths by gender, in total numbers A) and as percentage of all deaths B). Distributions for the years 2000, 2010, 2019, 2020 and 2021 are shown in subsequently lighter colors. Note the similarity of the 2021, 2020 and 2019 distributions of % deaths in (B). In 2021 and 2020, despite the increase in the number of opioid overdose deaths, they represented a similar percentage of total deaths in the US due to additional COVID-19 deaths[53].

The burden of the opioid epidemic is spread unequally across race and ethnic origin groups. Since the early-2000s, the highest death rates were among American Indian/Alaska Native (AI/AN) and white people (Figure 3A). However, the opioid overdose death rate of Black people surged since 2015, surpassing that of white people in 2020. In 2021, Black and AI/AN men experienced the highest age-adjusted death rates, at 51 and 46 deaths per 100,000 (Figure 3B). In 2021, the highest age-adjusted death rates in women were among AI/AN and Black women (31 and 18 deaths per 100,000, respectively).

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .



Figure 3: Burden of opioid overdose deaths by race and ethnicity in the United States. A) Opioid overdose death rates from 1999-2021, by race and ethnicity group. Dashed lines are death rates from 1999-2020 with the bridged-race categories, and solid lines are death rates from 2018-2021, with the new single race categories. The rates for Native Hawaiian and Other Pacific Islander and for More Than One Race were only reported separately in the new single race categories, starting in 2018. B) Age-adjusted death rates and C) years of life lost per capita, by race/ethnicity groups and by gender in 2021.

The life expectancy at birth (LE) of the US population is significantly shortened due to the opioid crisis. We found that LE was reduced by 0.44 years in 2019, 0.58 years in 2020, and 0.65 years in 2021 (Table 2) (see Methods). Subdividing by demographic group, we estimated that in 2019, the LE at birth of white men was reduced by the largest amount (0.70 years) followed by Black and AI/AN men (0.55 and 0.50 years, respectively). Amongst women, the LE at birth of AI/AN women was most reduced (0.39 years), followed by white and Black women (0.36 and 0.24 years, respectively). Each year from 2019 to 2021, there was an increase in the LE reduction in all demographic groups except Asian men. In 2021, the reduction of LE at birth of white men was still the largest (0.98 years) followed by Black and AI/AN men (0.96 years for both) (Table 2). Amongst women in 2021, the LE of AI/AN women was again reduced by the most (0.76 years), followed by white and Black women (0.50 and 0.44 years respectively).

Years of life lost is a metric taking into account the number of people dying at each age, and the difference between their age at death and their life expectancy. We estimate that nearly 3 million years of life were lost to opioid overdoses in the US in 2021 alone (Table 2). Nearly half (1.3 million years) were lost by white men, followed by white women (636,000 years), Hispanic men (308,000 years), and Black men (302,000 years). In total, 352,000 (14%) more years of life were lost to opioids in 2021 compared to 2020, and 634,000 (34%) more years of life were lost in 2020 than in 2019. There was a substantial increase in years of life lost (YLL) across all groups from 2019 to 2021, ranging from a 290% increase (Asian women) to a 38% increase (white women). In fact, despite losing the most years of life each year, white people actually saw the smallest relative increase from 2019 to 2021. The variation in size of the race/ethnic origin groups obscures differences in the YLL burden across the groups. However, the normalized YLL per capita allows for meaningful comparisons (Figure 3C). In 2021, AI/AN and Black men lost the most years per capita to the opioid crisis (1,500 years per 100,000 people), followed by white men (1,300 years per 100,000) (Figure 3C). Amongst women, AI/AN women lost the most years of life per capita in 2021 (1,100 years per 100,000). Amongst both men and women, Asian people lost the fewest years, around 200 and 40 years per 100,000 people, respectively.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Years of life lost		Hispanic	White	Black/African American	Asian	American Indian /Alaska Native	Total
2021	Female	91,945	635,899	139,517	4,520	13,887	
	Male	307,543	1,299,719	302,140	18,644	18,394	2,993,963
2020	Female	69,315	576,749	106,589	4,018	9,530	
	Male	255,139	1,192,684	239,495	19,785	14,661	2,629,807
2019	Female	48,727	459,579	74,579	1,570	6,991	
	Male	180,605	917,967	159,202	11,853	9,025	1,960,235
Reduction in life expectancy (years)							
2021	Female	0.21	0.50	0.44	0.03	0.76	
	Male	0.65	0.98	0.96	0.13	0.96	0.65
2020	Female	0.16	0.46	0.34	0.03	0.54	
	Male	0.54	0.91	0.78	0.14	0.78	0.58
2019	Female	0.12	0.36	0.24	0.01	0.39	
	Male	0.40	0.70	0.55	0.08	0.50	0.44

Table 2: Years of life lost in the US due to opioids. Years of life lost (top) and reduction in life expectancy (bottom) due to opioid overdose deaths in 2021, 2020 and 2021, by race and ethnicity group and by gender. We only report the years of life lost and the reduction in life expectancy for the 5 largest race and ethnicity groups. There was not enough data from the Native Hawaiian and Other Pacific Islanders group to estimate the years of life lost or the reduction in life expectancy (see Methods).

There is significant geographic variation in the severity of the opioid epidemic across the United States. In 2021, the most years of life (YLL) per capita were lost in West Virginia, at 2,400 years lost per 100,000 people, followed by Delaware and Tennessee (1,700 and 1,600 years per 100,000, respectively) (Figure 4A). Between 2019 and 2021, the YLL per capita more than tripled in Montana, Alaska, and Hawaii, and more than doubled in 12 additional states. In fact, during that time, the YLL per capita increased in all states except South Dakota, New Jersey, New Hampshire, and Delaware (Figure 4D). Similarly, the age-adjusted opioid overdose death rates more than doubled in 10 states between 2019 and 2021 (Figure 4E). Alaska, Louisiana, Mississippi, and Alabama had the largest relative increase in that period, with 2021 opioid overdose death rates about 2.5 times higher than in 2019, and New Hampshire was the only state in which this death rate decreased. In 2021, the age-adjusted opioid overdose death rate ranged from 77.2 deaths per 100,000 in West Virginia, to 5.7 in South Dakota (Figure 4B). In 2021, the percentage of all deaths of 25-44 year olds due to opioid overdoses was highest at 40.1% in Rhode Island, followed by West Virginia (36.6%) and Massachusetts (36.3%) (Figure 4C). In contrast, in South Dakota, Nebraska, and Hawaii, fewer than 7% of the deaths in 25-44 year olds were caused by opioids. Alabama and Mississippi had the largest relative increase in the percentage of deaths in 25-44 year olds that were due to opioid overdoses from 2019 to 2021, and 11 states had a decrease (Figure 4F). While there is geographic variation in the burden of the opioid crisis, the severity of the crisis worsened significantly across the United States. States in the South and the Midwest experienced the highest relative increases in burden, and New Hampshire was the only state with a decrease in burden across all metrics used here.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .



Figure 4: Geographic variation in the opioid epidemic in 2021 (top row) and relative change from 2019 (bottom row). A) and D) Years of life lost per capita due to opioid overdose deaths, by state, B) and E) Age-adjusted opioid overdose death rates by state, C) and F) Percentage of all deaths in 25-44 year olds that are opioid-related, by state. Gray indicates states for which years of life lost estimates were not possible in 2019, due to suppression of counts <10 (see Methods).

Discussion

The opioid crisis in the United States has been intensifying over the last 25 years, reaching 80,411 opioid overdose deaths in 2021. In this study, we estimate the years of life lost to the opioid crisis each year from 2019 to 2021. Here, years of life lost highlights both the large number of opioid overdose deaths, and how many of these deaths are among young people: opioid overdoses are a leading cause of death in young adults nationwide, causing more than 20% of all deaths in 20-39 year olds. We find the years of life lost (YLL) increased annually, reaching 3 million in 2021. We estimate 2 and 2.6 million YLL in 2019 and 2020, respectively, consistent with previous estimates of 1.7 million YLL in 2016 [39]. In particular, we found a 34% increase in YLL in 2020 compared to 2019. This surge in fatal opioid overdoses at the onset of the COVID-19 pandemic coincided with disruptions in access to treatment and harm reduction programs, and increased social isolation during lockdown periods [54–56].

Life expectancy in the United States has been stagnating or even declining since 2015 [57,58]. While this recent decline is due to a variety of factors, a significant portion is attributed to the opioid crisis [59] since individuals dying of opioid overdoses are much younger than those dying of other leading causes of death [36,60]. In this study, we estimated that in 2021 alone, the opioid crisis reduced the US population's life expectancy (LE) at birth by 0.65 years, compared to 0.44 years in 2019. We found the 2021 reduction in LE at birth varied across demographic groups,

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

from 0.98 years of LE lost for white men to 0.03 years for Asian women. While the burden of this crisis increased across all groups in the last few years, the increase was most pronounced for American Indian/Alaska Native (AI/AN) and Black or African American people, who now have the highest opioid overdose death rates. We also found that AI/AN men and Black men are now losing the most years of life per capita. The rapidly rising opioid overdose death rates among Black and AI/AN people are particularly concerning in light of the discrepancies in access to OUD treatment, resulting in lower initiation and retention rates among people of color [61,62]. These results add to previous work finding that, contrary to early beliefs and media portrayals of the opioid crisis, this is no longer simply a “rural white problem” [63].

This study provides further evidence that the opioid epidemic is still worsening at the national and state level, despite numerous efforts to turn the tide. While some interventions have been successful, some have had unintended or negative repercussions [64,65]. For example, while prescription drug monitoring programs were found to decrease prescription opioid mortality rates, without addressing existing OUD they may have contributed to the surge of illicitly manufactured opioid use [66]. And, despite the development of proven, effective treatments for OUD, stigmas impede access [67,68]. There is an urgent need for well-researched, multifaceted interventions, including stigma-reduction, in order to stabilize this constantly-evolving, deadly crisis [69].

Metrics based solely on overdose deaths are not complete measures of the burden of the opioid epidemic. Many people are impacted by this crisis in other ways. Individuals suffering from OUD have reduced quality of life [70] and impact the lives of family and community members. As an example, children in households with OUD face higher risk of behavioral problems and of involvement in the welfare system [71,72]. Additionally, there is significant economic cost from healthcare and reduced workforce participation due to OUD or early death [73,74]. OUD is also associated with increased risk of infection and death from bloodborne pathogens such as HIV and HCV, suggesting that the opioid crisis may be responsible for additional deaths [75–78]. Future work incorporating other metrics of burden such as nonfatal overdose hospitalization rates or elevated mortality rates from other causes may allow for a more complete picture.

Our YLL estimates are based on a lower bound of opioid overdose deaths. When stratifying deaths by demographic group, categories with fewer than 10 counts are suppressed by CDC WONDER for confidentiality reasons. In particular, smaller demographic groups with fewer total opioid-related deaths (even if death rates are high) have a higher number of suppressed categories, hence their burden is more underestimated than that of larger groups. Racial misclassification on death certificates may also be causing us to underestimate the opioid-related burden of smaller demographic groups, in particular for AI/AN people [79]. There is also likely underreporting of opioid overdose deaths, varying by state [80,81]. Altogether, this leads us to conclude that our results are underestimates of the annual years of life lost from the opioid crisis.

The continued rapid growth of the opioid epidemic highlights the importance and urgency of implementing more effective interventions to save hundreds of thousands of lives in just the next few years. We found that not only is the opioid crisis leading to several millions of years of life lost each year and significantly reducing life expectancy in the US, but these metrics are worsening each year. This study adds to the literature showing that the opioid epidemic is now most heavily impacting AI/AN and Black communities, and that the narrative of the opioid crisis primarily affecting white people is no longer accurate. An understanding of which are the vulnerable populations is imperative in order to implement effective and well-targeted interventions.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

References

1. *World Drug Report 2021*. United Nations publication, Sales No. E.21.XI.8
2. *Multiple Cause of Death by Single Race 2018-2021 on CDC WONDER (Wide-Ranging Online Data for Epidemiologic Research).* Centers for Disease Control, National Center for Health Statistics; 2022. Accessed April 12, 2023. Available at http://wonder.cdc.gov.
3. Vital Signs: Overdoses of Prescription Opioid Pain Relievers --- United States, 1999--2008. *Morb Mortal Wkly Rep MMWR*. Published online November 4, 2011. Accessed November 14, 2022. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm
4. Currie J, Schwandt H. The Opioid Epidemic Was Not Caused by Economic Distress but by Factors That Could Be More Rapidly Addressed. *Ann Am Acad Pol Soc Sci*. 2021;695(1):276-291. doi:10.1177/00027162211033833
5. Kolodny A. How FDA Failures Contributed to the Opioid Crisis. *AMA J Ethics*. 2020;22(8):743-750. doi:10.1001/amajethics.2020.743
6. Van Zee A. The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy. *Am J Public Health*. 2009;99(2):221-227. doi:10.2105/AJPH.2007.131714
7. *The President's Commission on Combating Drug Addiction and the Opioid Crisis*.; 2017.
8. Rep. Walden G [R O 2. H.R.6 - 115th Congress (2017-2018): SUPPORT for Patients and Communities Act. Published October 24, 2018. Accessed February 13, 2023. http://www.congress.gov/
9. Chisholm-Burns MA, Spivey CA, Sherwin E, Wheeler J, Hohmeier K. The opioid crisis: Origins, trends, policies, and the roles of pharmacists. *Am J Health Syst Pharm*. 2019;76(7):424-435. doi:10.1093/ajhp/zxy089
10. Dowell D. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. *MMWR Recomm Rep*. 2022;71. doi:10.15585/mmwr.rr7103a1
11. Guy GP. Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015. *MMWR Morb Mortal Wkly Rep*. 2017;66. doi:10.15585/mmwr.mm6626a4
12. Schuchat A, Houry D, Guy GP Jr. New Data on Opioid Use and Prescribing in the United States. *JAMA*. 2017;318(5):425-426. doi:10.1001/jama.2017.8913
13. U.S. Opioid Dispensing Rate Maps | Drug Overdose | CDC Injury Center. Published October 19, 2022. Accessed February 8, 2023. https://www.cdc.gov/drugoverdose/rxrate-maps/index.html
14. Schieber LZ, Guy GP Jr, Seth P, et al. Trends and Patterns of Geographic Variation in Opioid Prescribing Practices by State, United States, 2006-2017. *JAMA Netw Open*. 2019;2(3):e190665. doi:10.1001/jamanetworkopen.2019.0665
15. O'Donnell J, Gladden RM, Goldberger BA, Mattson CL, Kariisa M. Notes from the Field: Opioid-Involved Overdose Deaths with Fentanyl or Fentanyl Analogs Detected — 28 States and the District of Columbia, July 2016–December 2018. *Morb Mortal Wkly Rep*. 2020;69(10):271-273. doi:10.15585/mmwr.mm6910a4
16. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Opioid Data Analysis and Resources. Accessed May 31, 2023. https://www.cdc.gov/opioids/data/analysis-resources.html
17. Garcia GGP, Stringfellow EJ, DiGennaro C, et al. Opioid overdose decedent characteristics during COVID-19. *Ann Med*. 2022;54(1):1081-1088. doi:10.1080/07853890.2022.2067350

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

18. Soares WE, Melnick ER, Nath B, et al. Emergency Department Visits for Nonfatal Opioid Overdose During the COVID-19 Pandemic Across Six US Health Care Systems. *Ann Emerg Med*. 2022;79(2):158-167. doi:10.1016/j.annemergmed.2021.03.013
19. Friedman J, Akre S. COVID-19 and the Drug Overdose Crisis: Uncovering the Deadliest Months in the United States, January July 2020. *Am J Public Health*. 2021;111(7):1284-1291. doi:10.2105/AJPH.2021.306256
20. Brat GA, Agniel D, Beam A, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. *The BMJ*. 2018;360:j5790. doi:10.1136/bmj.j5790
21. Mojtabai R, Amin-Esmaeili M, Nejat E, Olfson M. Misuse of prescribed opioids in the United States. *Pharmacoepidemiol Drug Saf*. 2019;28(3):345-353. doi:10.1002/pds.4743
22. Han BH, Sherman SE, Palamar JJ. Prescription opioid misuse among middle-aged and older adults in the United States, 2015–2016. *Prev Med*. 2019;121:94-98. doi:10.1016/j.ypmed.2019.02.018
23. Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT. Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study. *PLOS Med*. 2019;16(11):e1002922. doi:10.1371/journal.pmed.1002922
24. Ford JA, Pomykacz C, Szalewski A, McCabe SE, Schepis TS. Friends and relatives as sources of prescription opioids for misuse among young adults: The significance of physician source and race/ethnic differences. *Subst Abuse*. 2020;41(1):93-100. doi:10.1080/08897077.2019.1635955
25. Schepis TS, Wastila L, Ammerman B, McCabe VV, McCabe SE. Prescription Opioid Misuse Motives in US Older Adults. *Pain Med*. 2020;21(10):2237-2243. doi:10.1093/pm/pnz304
26. Han B, Compton WM, Blanco C, Jones CM. Correlates of Prescription Opioid Use, Misuse, Use Disorders, and Motivations for Misuse Among US Adults. *J Clin Psychiatry*. 2018;79(5):15323. doi:10.4088/JCP.17m11973
27. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. *Ann Intern Med*. 2017;167(5):293. doi:10.7326/M17-0865
28. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. *PAIN*. 2015;156(4):569. doi:10.1097/01.j.pain.0000460357.01998.f1
29. Mintz CM, Hartz SM, Borodovsky JT, Bierut LJ, Grucza RA. Changes in associations between prescription opioid use disorder and illegal behaviors among adults in the United States from 2002 to 2014. *Addiction*. 2019;114(12):2150-2159. doi:10.1111/add.14638
30. Scorsone KL, Haozous EA, Hayes L, Cox KJ. Ending the Chase: Experiences of Rural Individuals with Opioid Use Disorder. *Subst Use Misuse*. 2021;56(8):1224-1231. doi:10.1080/10826084.2021.1914109
31. Strang J, Volkow ND, Degenhardt L, et al. Opioid use disorder. *Nat Rev Dis Primer*. 2020;6(1):1-28. doi:10.1038/s41572-019-0137-5
32. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. *Addiction*. 2011;106(1):32-51. doi:10.1111/j.1360-0443.2010.03140.x
33. Hser YI, Mooney LJ, Saxon AJ, et al. High Mortality among Patients with Opioid Use Disorder in a Large Healthcare System. *J Addict Med*. 2017;11(4):315-319. doi:10.1097/ADM.0000000000000312
34. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019 | Adolescent Medicine | JAMA Network Open | JAMA Network. Accessed March 29, 2023. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790432?resultClick=3

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

35. Wakeman SE, Larochelle MR, Ameli O, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. *JAMA Netw Open*. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622
36. Centers for Disease Control and Prevention. State Unintentional Drug Overdose Reporting System (SUDORS). Atlanta, GA: US Department of Health and Human Services, CDC. Accessed June 3, 2023. https://www.cdc.gov/drugoverdose/fatal/dashboard/index.html
37. Marshall RJ. Standard Expected Years of Life Lost as a Measure of Disease Burden: An Investigation of Its Presentation, Meaning and Interpretation. In: Preedy VR, Watson RR, eds. *Handbook of Disease Burdens and Quality of Life Measures*. Springer; 2010:401-413. doi:10.1007/978-0-387-78665-0_22
38. Gomes T, Mamdani MM, Dhalla IA, Cornish S, Paterson JM, Juurlink DN. The burden of premature opioid-related mortality. *Addiction*. 2014;109(9):1482-1488. doi:10.1111/add.12598
39. Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The Burden of Opioid-Related Mortality in the United States. *JAMA Netw Open*. 2018;1(2):e180217. doi:10.1001/jamanetworkopen.2018.0217
40. Hall OT, Hall OE, McGrath RP, Haile ZT. Years of Life Lost due to Opioid Overdose in Ohio: Temporal and Geographic Patterns of Excess Mortality. *J Addict Med*. 2020;14(2):156-162. doi:10.1097/ADM.0000000000000554
41. Amiri S, Pham CD, Castonguay S, Denney JT, Buchwald DS. Deaths associated with opioids, race and ethnicity, and years of potential life lost in Washington State. *J Subst Abuse Treat*. 2022;139:108789. doi:10.1016/j.jsat.2022.108789
42. Hermans SP, Samiec J, Golec A, Trimble C, Teater J, Hall OT. Years of Life Lost to Unintentional Drug Overdose Rapidly Rising in the Adolescent Population, 2016–2020. *J Adolesc Health*. 2023;72(3):397-403. doi:10.1016/j.jadohealth.2022.07.004
43. Harris RA, Mandell DS. Years of Life Lost to Drug Overdose Among Black Female Individuals in the US, 2015-2021. *JAMA Psychiatry*. 2023;80(3):276-277. doi:10.1001/jamapsychiatry.2022.4194
44. Dowell D, Arias E, Kochanek K, et al. Contribution of Opioid-Involved Poisoning to the Change in Life Expectancy in the United States, 2000-2015. *JAMA*. 2017;318(11):1065-1067. doi:10.1001/jama.2017.9308
45. Kiang MV, Basu S, Chen J, Alexander MJ. Assessment of Changes in the Geographical Distribution of Opioid-Related Mortality Across the United States by Opioid Type, 1999-2016. *JAMA Netw Open*. 2019;2(2):e190040. doi:10.1001/jamanetworkopen.2019.0040
46. Lozano G. The Opioid Crisis And Life Expectancy In The U.S. *Joseph Whart Sch*. Published online May 4, 2020. https://repository.upenn.edu/joseph_wharton_scholars/88
47. Arias E, Xu J. United States Life Tables, 2020. *Natl Vital Stat Rep Hyattsville MD Natl Cent Health Stat*. 2022;71(1). doi:https://dx.doi.org/10.15620/cdc:118055.
48. Arias E, Xu J. United States Life Tables, 2019. *Natl Vital Stat Rep Hyattsville MD Natl Cent Health Stat*. 2022;70(19):59. doi:https://dx.doi.org/10.15620/cdc:113096.
49. Olivieri A, Pitacco E. Life tables in actuarial models: from the deterministic setting to a Bayesian approach. *AStA Adv Stat Anal*. 2012;96(2):127-153. doi:10.1007/s10182-011-0177-y
50. Siegel J. *The Demography and Epidemiology of Human Health and Aging*. Accessed July 1, 2022. https://link.springer.com/book/10.1007/978-94-007-1315-4
51. Preston S, Heuveline P, Guillot M. *Demography: Measuring and Modeling Population Processes | Wiley*. Accessed July 25, 2022. https://www.wiley.com/en-us/Demography%3A+Measuring+and+Modeling+Population+Processes-p-9781557864512
52. Synthetic Opioid Overdose Data | Drug Overdose | CDC Injury Center. Published June 6, 2022. Accessed September 27, 2022. https://www.cdc.gov/drugoverdose/deaths/synthetic/index.html
53. Bureau UC. Pandemic Disrupted Historical Mortality Patterns, Caused Largest Jump in Deaths in 100 Years. Census.gov. Accessed June 21, 2023.

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

https://www.census.gov/library/stories/2022/03/united-states-deaths-spiked-as-covid-19-continued.html

54. Glick SN, Prohaska SM, LaKosky PA, Juarez AM, Corcorran MA, Des Jarlais DC. The Impact of COVID-19 on Syringe Services Programs in the United States. *AIDS Behav*. 2020;24(9):2466-2468. doi:10.1007/s10461-020-02886-2
55. Joudrey PJ, Adams ZM, Bach P, et al. Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada. *JAMA Netw Open*. 2021;4(7):e2118223. doi:10.1001/jamanetworkopen.2021.18223
56. Wakeman SE, Green TC, Rich J. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. *Nat Med*. 2020;26(6):819-820. doi:10.1038/s41591-020-0898-0
57. Venkataramani AS, O'Brien R, Tsai AC. Declining Life Expectancy in the United States: The Need for Social Policy as Health Policy. *JAMA*. 2021;325(7):621-622. doi:10.1001/jama.2020.26339
58. Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2021. *NCHS Data Brief*. 2022;(456).
59. Harper S, Riddell CA, King NB. Declining Life Expectancy in the United States: Missing the Trees for the Forest. *Annu Rev Public Health*. 2021;42(1):381-403. doi:10.1146/annurev-publhealth-082619-104231
60. WISQARS Leading Causes of Death Reports, 1981 - 2020. Centers for Disease Control and Prevention. https://wisqars.cdc.gov/fatal-leading
61. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder. doi:10.1377/hlthaff.2020.02261
62. Santoro TN, Santoro JD, Santoro TN, Santoro JD. Racial Bias in the US Opioid Epidemic: A Review of the History of Systemic Bias and Implications for Care. *Cureus*. 2018;10(12). doi:10.7759/cureus.3733
63. Gondré-Lewis MC, Abijo T, Gondré-Lewis TA. The Opioid Epidemic: a Crisis Disproportionately Impacting Black Americans and Urban Communities. *J Racial Ethn Health Disparities*. Published online September 6, 2022. doi:10.1007/s40615-022-01384-6
64. Evans WN, Lieber EMJ, Power P. How the Reformulation of OxyContin Ignited the Heroin Epidemic. *Rev Econ Stat*. 2019;101(1):1-15. doi:10.1162/rest_a_00755
65. Roberts AW, Farley JF, Holmes GM, et al. Controlled Substance Lock-In Programs: Examining An Unintended Consequence Of A Prescription Drug Abuse Policy. *Health Aff (Millwood)*. 2016;35(10):1884-1892. doi:10.1377/hlthaff.2016.0355
66. Lee B, Zhao W, Yang KC, Ahn YY, Perry BL. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018. *JAMA Netw Open*. 2021;4(2):e2036687. doi:10.1001/jamanetworkopen.2020.36687
67. Madras BK, Ahmad NJ, Wen J, Sharfstein JS. Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System. *NAM Perspect*. 2020:10.31478/202004b. doi:10.31478/202004b
68. The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy. doi:10.2147/SAR.S304566
69. Madden EF, Prevedel S, Light T, Sulzer SH. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review. *Subst Use Misuse*. 2021;56(14):2181-2201. doi:10.1080/10826084.2021.1975749
70. Association of current and past opioid use disorders with health-related quality of life and employment among US adults. *Drug Alcohol Depend*. 2019;199:122-128. doi:10.1016/j.drugalcdep.2019.03.004
71. Winstanley EL, Stover AN. The Impact of the Opioid Epidemic on Children and Adolescents. *Clin Ther*. 2019;41(9):1655-1662. doi:10.1016/j.clinthera.2019.06.003

medRxiv preprint doi: https://doi.org/10.1101/2023.07.07.23292297; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

72. Romanowicz M, Vande Voort JL, Shekunov J, et al. The effects of parental opioid use on the parent–child relationship and children's developmental and behavioral outcomes: a systematic review of published reports. *Child Adolesc Psychiatry Ment Health*. 2019;13(1):5. doi:10.1186/s13034-019-0266-3
73. Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. *Drug Alcohol Depend*. 2021;218:108350. doi:10.1016/j.drugalcdep.2020.108350
74. Murphy SM. The cost of opioid use disorder and the value of aversion. *Drug Alcohol Depend*. 2020;217:108382. doi:10.1016/j.drugalcdep.2020.108382
75. Causes of Death After Nonfatal Opioid Overdose - PMC. Accessed May 23, 2023. https://www-ncbi-nlm-nih-gov.proxy1.library.jhu.edu/pmc/articles/PMC6143082/
76. Suryaprasad AG, White JZ, Xu F, et al. Emerging Epidemic of Hepatitis C Virus Infections Among Young Nonurban Persons Who Inject Drugs in the United States, 2006–2012. *Clin Infect Dis*. 2014;59(10):1411-1419. doi:10.1093/cid/ciu643
77. Broz D, Zibbell J, Foote C, et al. Multiple injections per injection episode: High-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana. *Int J Drug Policy*. 2018;52:97-101. doi:10.1016/j.drugpo.2017.12.003
78. Anderson ES, Russell C, Basham K, et al. High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department. *PLoS ONE*. 2020;15(6):e0233927. doi:10.1371/journal.pone.0233927
79. Dougherty TM, Janitz AE, Williams MB, et al. Racial Misclassification in Mortality Records Among American Indians/Alaska Natives in Oklahoma From 1991 to 2015. *J Public Health Manag Pract*. 2019;25:S36. doi:10.1097/PHH.0000000000001019
80. Buchanich JM, Balmert LC, Williams KE, Burke DS. The Effect of Incomplete Death Certificates on Estimates of Unintentional Opioid-Related Overdose Deaths in the United States, 1999-2015. *Public Health Rep*. 2018;133(4):423-431. doi:10.1177/0033354918774330
81. Slavova S, O'Brien DB, Creppage K, et al. Drug Overdose Deaths: Let's Get Specific. *Public Health Rep*. 2015;130(4):339-342. Accessed June 1, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547584/